Table 1. Comparison of the DCE and DW MR parameters among control, erlotinib, and combined erlotinib and bevacizumab (BEV) groups in HCC827.
| HCC 827 | Baseline | Week 1 | Week 2 |
|---|---|---|---|
| iAUC90 | |||
| Ctrl | 142.4 ± 28.4 | 188.1 ± 112.0 | 323.4 ± 88.7 |
| erlotinib | 353.2 ± 103.3 | 306.6 ± 118.6 | 196.2 ± 90.5† |
| erlotinib+BEV | 391.4 ± 176.0 | 180.4 ± 73.7*‡ | 122.7 ± 68.6* |
| Ktrans (min-1) | |||
| Ctrl (min-1) | 65.4 ± 19.4 | 85.2 ± 33.6 | 159.9 ± 37.8 |
| erlotinib | 143.7 ± 57.4 | 115.0 ± 36.1 | 77.5 ± 49.7† |
| erlotinib+BEV | 101.7 ± 33.4 | 85.9 ± 39.8 | 63.5 ± 43.3* |
| kep (min-1) | |||
| Ctrl | 172.6 ± 33.4 | 274.9 ± 138.4 | 716.6 ± 183.2 |
| erlotinib | 580.8 ± 132.9 | 356.5 ± 127.2† | 222.6 ± 132.5† |
| erlotinib+BEV | 300.3 ± 80.9 | 241.4 ± 108.2* | 163.4 ± 81.6* |
| ADC (×106 mm2) | |||
| Ctrl | 1432.4 ± 488.8 | 1342.8 ± 311.8 | 1194.7 ± 275.9 |
| erlotinib | 1170.7 ± 162.7 | 2071.1 ± 685.9† | 2992.5 ± 1595.8† |
| erlotinib+BEV | 1352.9 ± 629.1 | 1461.9 ± 671.4 | 1581.4 ± 302.9* |
| Ve | |||
| Ctrl | 365.3 ± 137.7 | 534.5 ± 326.7 | 267.1 ± 89.3 |
| erlotinib | 477.7 ± 313.6 | 316.4 ± 93.2 | 263.9 ± 111.1 |
| erlotinib+BEV | 362.9 ± 76.0 | 389.8 ± 173.8 | 400.6 ± 441.1 |
| Vp | |||
| Ctrl | 98.8 ± 80.6 | 76.5 ± 44.1 | 80.1 ± 52.5 |
| erlotinib | 115.9 ± 67.5 | 89.5 ± 69.8 | 68.4 ± 69.2 |
| erlotinib+BEV | 52.7 ± 25.4 | 57.3 ± 53.6 | 98.5 ± 67.8 |
Ctrl, control (without treatment); BEV, bevacizumab
Data presented were mean absolute value ± standard deviation (S.D.).
The P values were obtained from the paired t-test or Wilcoxon signed-rank test.
†, p <0.05 for comparison between “Ctrl” and “erlotinib”.
*, p < 0.05 for comparison between “Ctrl” and “erlotinib combined with BEV”.
‡, p < 0.05 for comparison between “erlotinib” and “erlotinib combined with BEV”.